Ernexa Therapeutics Inc. Common Stock

ERNANASDAQ • USD
ThemeHealthcare - Oncology›Cell & Gene Therapy for Cancer
7.89 USD
↘ 0.30 (3.66%)AT CLOSE (11:59 AM EDT)
8.08
↗ 0.20 (2.47%)
POST MARKET (AS OF 06:19 PM EDT)
Post Market
AS OF 06:19 PM EDT
8.08
↗ 0.20 (2.47%)
🔴Market: CLOSED
Open?$8.03
High?$8.32
Low?$7.65
Prev. Close?$8.19
Volume?36.8K
Avg. Volume?3.5M
VWAP?$7.87
Rel. Volume?0.01x
Bid / Ask
Bid?$7.65 × 1.0K
Ask?$8.50 × 1.5K
Spread?$0.85
Midpoint?$8.08
Valuation & Ratios
Market Cap?9.2M
Shares Out?1.2M
Float?13.7M
Float %?46.9%
P/E Ratio?N/A
P/B Ratio?1.34
EPS?-$9.78
Dividend?0.00%
Ex-Dividend?N/A

Ernexa Therapeutics Inc. Common Stock (ERNA) is currently trading at $7.89. The stock presents a bearish profile across the board: technical indicators signal "Strong Sell" and our fundamental models agree with a "Sell" rating. This is driven by a concerning Altman Z-Score in the distress zone, a weak Piotroski F-Score of 0/9, negative Return on Equity and a bearish Death Cross on the long-term moving averages. Valuation metrics suggest ERNA is trading at a discount to its peers, earning an "Attractively Valued" rating.

Technical & fundamental data as of Jun 5, 2026.

News
Profile
Ernexa Therapeutics Inc is a preclinical-stage synthetic allogeneic iMSC therapy company developing medicines to treat various forms of cancer and other diseases with high unmet medical needs. Its main product candidate, ERNA-101, capitalizes on the intrinsic tumor-homing ability of MSCs (mesenchymal stem cells) to slip through the tumor's defenses and to deliver potent pro-inflammatory factors directly to the tumor microenvironment. The firm's initial focus is to develop ERNA-101 in platinum-resistant ovarian cancer. Through another product candidate, ERNA-201, it is investigating anti-inflammatory cytokine (IL-10) secreting iMSCs in autoimmune disorders like rheumatoid arthritis. The company operates in a single reportable segment, the research and development of cellular therapies.
Themes
Healthcare - Oncology›Cell & Gene Therapy for CancerBiotech - Drug Development›Immunology & Autoimmune
Employees
5
Market Cap
9.2M
Industry
PHARMACEUTICAL PREPARATIONS
Website
www.ernexatx.com
Listed
2021-03-26
Address
1035 CAMBRIDGE STREET
CAMBRIDGE, MA 02141
Phone: (617) 798-6700
Technical OutlookStrong Sell
Strong SellNeutralStrong Buy
Long-Term (Tide)?▼ Bearish(-2/3)
Medium-Term (Wave)?▼ Bearish(-2/3)
Short-Term (Ripple)?▼ Bearish(-3/3)
MA Alignment?Mixed
Full Technical Analysis →
Fundamental OutlookSell
Strong SellNeutralStrong Buy
F-Score?
3
Z-Score?
0
Momentum?
77
Short Sent.?
60
Piotroski F-Score?0/9Weak
Altman Z-Score?-34.92Distress
Confidence?41%Low
Full Fundamental Analysis →
Short InterestLow
Short % of Float?1.19%Low
Short Interest?162.6K
Days to Cover?1.0
Free Float13.7M
Avg Daily Volume8.8M
Settlement Date2026-05-15
Financial Health
Current Ratio?2.89Strong
Quick Ratio?2.89Strong
Cash Ratio?2.65Strong
Debt/Equity?0.00Low
ValuationATTRACTIVELY VALUEDvs 1 peers + S&P 500
Score
100/100
P/E?
N/A▾
P/B?
Peers
100
S&P
91
1.34CHEAP▾
P/S?
N/A▾
P/FCF?
N/A▾
EV/EBITDA?
S&P
97
-0.0CHEAP▾
EV/Sales?
N/A▾
Returns & Efficiency
ROE?
S&P
3
-166.3%WEAK▾
ROA?
S&P
3
-108.2%WEAK▾
Cash Flow & Enterprise
FCF?$-7255000
Enterprise Value?$25.4K
Fundamentals ratios updated end of day
MarketsMoversWatchlist